Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by consultant99on Oct 13, 2022 8:29pm
468 Views
Post# 35023862

Up Up and Away?

Up Up and Away?

TD Waterhouse technical resource has an intermediate buy on TLT with an expected range of 0.33 - 0.35 

Yea not that great but you have to start so,e where. Once the PP is directly out of the way we will still be dealing with profit taking and those that bought the PP and will be liquidating a piece to reduce their risk.

Nevertheless we know there is a lot of potentially positive news coming in Q4 so the intermediate buy range is but a short term step in the move to fill the price gap above the market and eventually to move to multi year highs around 0.75

My projection is over $1 by Q1 2023 assuming good news. The vaccine trial is where I see the greatest upside leverage in the short run - keep in mind that the analysts have assigned no value to it in their valuation model.

The lack of information from the company is not helping. Their last corporate update was in June. They have not articulated a vision of how they would capitalize if and when they get BTD & AA on the bladder side and a positive Covid animal trial on the vaccine side.

Scanning the company website is not helpful. They stop posting newsletters. Their Corporate Factsheet is years old. They stated that once a majority of clincs for the phase 2 trial were setup they would begin Phase 1 trials for lung/brain cancer. As far as I can tell they have never gotten to the expected number of trial locations. It would be helpful to understand why and whether they are now doing procedures in each location. 


As I have said before I have more questions than answers, do you? At some point in time the company will need to start answering those questions, fill in the blanks so to speak, if they want to grow the share price. Continuing to fish in this shareholder pond for equity is not doing it and the company is going to continue to need money for development and commercialization. 

<< Previous
Bullboard Posts
Next >>